Peer review reports
From: Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Original Submission | ||
---|---|---|
22 Aug 2023 | Submitted | Original manuscript |
24 Sep 2023 | Reviewed | Reviewer Report |
18 Oct 2023 | Reviewed | Reviewer Report |
8 Nov 2023 | Author responded | Author comments - Zhengliang Tu |
Resubmission - Version 2 | ||
8 Nov 2023 | Submitted | Manuscript version 2 |
10 Nov 2023 | Author responded | Author comments - Zhengliang Tu |
Resubmission - Version 3 | ||
10 Nov 2023 | Submitted | Manuscript version 3 |
11 Nov 2023 | Author responded | Author comments - Zhengliang Tu |
Resubmission - Version 4 | ||
11 Nov 2023 | Submitted | Manuscript version 4 |
23 Nov 2023 | Reviewed | Reviewer Report |
5 Dec 2023 | Reviewed | Reviewer Report |
7 Dec 2023 | Author responded | Author comments - Zhengliang Tu |
Resubmission - Version 5 | ||
7 Dec 2023 | Submitted | Manuscript version 5 |
Publishing | ||
12 Dec 2023 | Editorially accepted | |
21 Dec 2023 | Article published | 10.1186/s12885-023-11745-x |